QPPV.COM KNOWLEDGE ASSESSMENT

13-Valent Pneumococcal Conjugate Vaccine: Immunology, Serotype Coverage and Pharmacovigilance

Test your understanding of the concepts covered by 13-Valent Pneumococcal Conjugate Vaccine: Immunology, Serotype Coverage and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 For adverse-event cases, the article lists useful minimum context. Which of the following is NOT explicitly mentioned as part of that minimum context?

Exact vaccine and lot number Dose number and age Patient's occupation Co-administered vaccines and previous pneumococcal vaccines

Question 2 of 10 According to the article, what is the recommended approach for very premature infants regarding apnoea risk after vaccination?

They should never receive the vaccine They require clinical consideration of apnoea risk and monitoring They must be hospitalised for 24 hours after every dose The vaccine is contraindicated for all preterm infants

Question 3 of 10 Why does the article highlight the importance of a history of severe allergic reaction to diphtheria-toxoid-containing products?

Because the vaccine contains diphtheria toxoid as an adjuvant Because CRM197 is a non-toxic diphtheria-derived carrier protein Because diphtheria toxoid is used as a preservative in the vaccine Because the vaccine is contraindicated in all individuals with a diphtheria allergy

Question 4 of 10 The article emphasises that aggregate surveillance should keep separate which two types of questions?

Reactogenicity and effectiveness Safety and efficacy Immunogenicity and adverse events Product quality and distribution

Question 5 of 10 In infants and children, multiple vaccines are frequently administered at the same visit. The article advises that temporal association alone should:

Always assign causality to the 13-valent vaccine Assign causality to the most reactogenic vaccine Not assign causality to one component Be ignored in pharmacovigilance assessments

Question 6 of 10 Before interpreting a post-vaccination infection as potential vaccine failure, the article recommends which of the following steps?

Only clinical characterisation Only microbiological characterisation Both clinical and microbiological characterisation No characterisation is needed

Question 7 of 10 The article explains that conjugation to CRM197 converts purified bacterial carbohydrates into antigens capable of generating stronger T-cell-dependent responses. Which of the following is a direct consequence of this design?

The vaccine requires an adjuvant to be effective It promotes class switching, affinity maturation, and memory It eliminates the need for booster doses It makes the vaccine effective against all pneumococcal serotypes

Question 8 of 10 Failing to capture serotype in breakthrough disease is a failure mode because it prevents:

Determining the patient's age Distinguishing vaccine-type from non-vaccine-type infection Assessing the lot number Measuring reactogenicity

Question 9 of 10 The article notes that immunocompromised patients may have reduced immune responses. How should this be interpreted in pharmacovigilance?

It is primarily an effectiveness consideration, but their underlying disease and therapies also complicate adverse-event attribution It means they should never receive the vaccine It eliminates the need for serotype confirmation in breakthrough disease It guarantees that any adverse event is vaccine-related

Question 10 of 10 If a vaccinated patient develops pneumonia caused by a serotype not included in the 13-valent vaccine, which of the following interpretations is most appropriate according to the article?

The vaccine failed to protect against that serotype This is a vaccine-type breakthrough This infection does not demonstrate failure of the vaccine against its intended serotypes The patient likely received an incorrect vaccine valency

13-Valent Pneumococcal Conjugate Vaccine: Immunology, Serotype Coverage and Pharmacovigilance

Cookie Settings